Revenue Recovery Begins, but Pooph® Damage Defines the Baseline

Validated platforms begin commercial transition as Clyra enters distribution and PFAS deployment advances, yet 2025 financials confirm Pooph® collapse as a defining event.

BioLargo Inc | OTCQX: BLGO | Investing.com

BioLargo’s (OTCQX: BLGO) trajectory has materially evolved since TradersQue’s previous 2025 analyses. The company has since crossed key operational thresholds: Clyra Medical has entered commercial distribution, and the AEC PFAS system has been installed at a municipal site.

However, these advances arrive in the shadow of a severe full-year financial contraction, driven by the collapse of the Pooph® licensing relationship. The result is a company closer to execution and thus to a more legitimate valuation.

Updated Finances

Our November 2025 analysis used Q3 figures to show a company under pressure but still liquid. The full-year 2025 results refine that picture, including the scale of the Pooph® fallout:

*Year-end equity here is implied by assets less liabilities using the year-end figures BioLargo reported publicly.

From Promise to Pause: BioLargo’s Cautious Q3 | TradersQue

The company preserved cash better than revenue, but equity pressure intensified, suggesting BioLargo remains operationally alive and capable of funding near-term commercialization work, yet still has very limited room for misses if new platforms do not begin producing meaningful revenue in 2026.

Segment Updates

Pooph® / CupriDyne

This remains the clearest confirmation of TradersQue’s prior risk assessment. BioLargo revoked the Pooph® license in September 2025 over roughly $3.8 million in alleged unpaid obligations, then filed a federal lawsuit in November 2025 alleging breach of contract, patent infringement, false advertising, and related claims. In the lawsuit announcement, BioLargo said it sought, among other things, $1.7 million in unpaid royalties and $2.2 million for unpaid product purchases. Meanwhile, the Q3 2025 filing recorded a $3.9 million credit loss expense tied to Pooph® receivables.

TradersQue’s original warning remains central to our investment case moving forward. Until litigation produces recovery or BioLargo successfully redeploys the technology commercially elsewhere, Pooph® shifts from former revenue engine to legal overhang.

Clyra Medical / ViaCLYR™

This is the most improved segment. The prior concern was that BioLargo kept presenting Clyra as “near launch” without actual sales proof. That concern is now partially relieved because the company has announced a first stocking order, national distribution availability through Advanced Solutions, and external clinical visibility from a January 2026 Boswick Symposium presentation covering approximately 36 cases across four wound clinics over four months. Clinicians reported rapid wound transformation, drainage reduction, and no adverse reactions in the experience presented.

Still, investors should separate commercial start from commercial scale. A first stocking order is important, but it does not yet answer questions around reorder cadence, formulary depth, gross margin mix, or recurring demand. So the risk has changed from “is Clyra ever really launching?” to “can Clyra convert early validation into measurable repeat sales?”

Although a genuine commercialization story, Clyra remains in early-stage commercialization without established proof of broad uptake to date.

PFAS / AEC platform

The AEC platform remains stuck in the regulatory-to-revenue gap as it continues operating at the Lake Stockholm, NJ, municipal water treatment plant. The remaining limitation is that the system must complete commissioning and then generate operating data during this 12-month NJDEP monitoring period.

GHG Deregulation Does Not Derail PFAS | TradersQue

That means the PFAS thesis is stronger technically and commercially than it had been in 2025, but backlog conversion still depends on outside validation, permitting, and procurement. Put differently, the platform is moving from pre-commercial demonstration toward reference-site qualification, which is a meaningful step, but still not the same as repeatable revenue deployment.

Cellinity™ Battery Platform

BioLargo’s continues to frame Cellinity™ as strategically important, noting $425,000 of financing cash flow for BioLargo Energy in 2025. Cellinity™ remains strategically interesting but needs contract conversion and capital-backed commercialization proof to establish a firmer valuation. This division will prove exceptionally valuable once scaled, but battery evolution requires significant time, support, and capital in the interim.

Final Thoughts

TradersQue’s previous analysis argued that valuation depended less on validation and more on conversion. The difference today is that BioLargo can now point to actual first-step conversion events: Clyra has entered commercial distribution, and AEC has reached municipal installation. Those are important advances and make the business more credible than prior updates.

But the bearish side of the original thesis also remains intact. Full-year 2025 results show that the Pooph® breakdown was severe enough to overwhelm progress elsewhere in the near term.

New revenue streams can emerge fast enough to stabilize the enterprise, but revenues collectively must improve to retain current investors and attract new ones.

About BioLargo, Inc.

BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. The company’s core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. BioLargo, Inc.’s approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.

Investors can tune into scheduled earnings calls and access related documents via BioLargo’s investor relations page.

Additional Coverage

Please review our archives for past coverage on BioLargo, Inc. TradersQue.com remains loyal to and confident of BioLargo, Inc.’s near-term future and long-term future.

TradersQue Archives – BioLargo, Inc.

Additional social media coverage can be found on X.